PL3277272T3 - Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego - Google Patents

Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego

Info

Publication number: PL3277272T3
Authority: PL; Poland
Prior art keywords: stratification; patients; treatment; methods; receptor agonists
Prior art date: 2015-03-31

Application number

PL16774191T

Other languages

English (en)

Inventor

Mei Wei CHEN

Cindy COLLINS

Matthew Lucas EATON

Matthew G. Guenther

Nan KE

Jeremy LOPEZ

Michael R. Mckeown

David A. Orlando

Original Assignee

Syros Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-31

Filing date

2016-03-31

Publication date

2022-01-24

2016-03-31 Application filed by Syros Pharmaceuticals, Inc. filed Critical Syros Pharmaceuticals, Inc.

2022-01-24 Publication of PL3277272T3 publication Critical patent/PL3277272T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL16774191T 2015-03-31 2016-03-31 Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego PL3277272T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562140999P	2015-03-31	2015-03-31
US201562268203P	2015-12-16	2015-12-16
EP16774191.7A EP3277272B1 (en)	2015-03-31	2016-03-31	Methods of stratifying patients for treatment with retinoic acid receptor-agonists
PCT/US2016/025256 WO2016161107A1 (en)	2015-03-31	2016-03-31	METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS

Publications (1)

Publication Number	Publication Date
PL3277272T3 true PL3277272T3 (pl)	2022-01-24

Family

ID=57006493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16774191T PL3277272T3 (pl)	2015-03-31	2016-03-31	Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego

Country Status (14)

Country	Link
US (5)	US9845508B2 (pl)
EP (2)	EP3277272B1 (pl)
JP (4)	JP6952604B2 (pl)
KR (1)	KR20170132248A (pl)
CN (2)	CN116059365A (pl)
AU (3)	AU2016243702B2 (pl)
BR (3)	BR112017020745A2 (pl)
CA (1)	CA2981518C (pl)
ES (1)	ES2901792T3 (pl)
HU (1)	HUE057325T2 (pl)
IL (3)	IL294449B2 (pl)
MX (2)	MX391949B (pl)
PL (1)	PL3277272T3 (pl)
WO (1)	WO2016161107A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2969031A4 (en)	2013-03-15	2017-03-08	Avisenna Cosmetics LLC	Topical compositions for reducing aging effects
EP3277272B1 (en) *	2015-03-31	2021-08-04	Syros Pharmaceuticals, Inc.	Methods of stratifying patients for treatment with retinoic acid receptor-agonists
KR20240157122A (ko)	2016-04-08	2024-10-31	사이로스 파마수티컬스, 인크.	Aml 및 mds 치료용 rara 효능제
TW201823471A (zh) *	2016-10-06	2018-07-01	美商錫羅斯製藥公司	以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
WO2018136961A1 (en) *	2017-01-23	2018-07-26	Syros Pharmaceuticals Inc.	METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
JP2019043865A (ja) *	2017-08-31	2019-03-22	ひまわり製薬株式会社	ざ瘡様疾患を治療又は予防するための皮膚外用組成物
WO2020069187A1 (en) *	2018-09-28	2020-04-02	The Children's Medical Center Corporation	Combination therapy for acute myeloid leukemia
BR112023002004A2 (pt) *	2020-08-06	2023-04-04	Syros Pharmaceuticals Inc	Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2
CN112390731B (zh) *	2020-11-16	2022-11-25	成都大学	一种具有多靶点的维甲酸类衍生物及其制备方法与应用
JP7837529B1 (ja) *	2024-11-06	2026-03-31	国立大学法人京都大学	常染色体顕性（優性）多発性嚢胞腎治療用医薬組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0170105B1 (en)	1984-07-07	1990-10-17	Koichi Prof. Dr. Shudo	Benzoic acid derivatives
US5089509A (en)	1988-09-15	1992-02-18	Allergan, Inc.	Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2752630B2 (ja)	1988-03-29	1998-05-18	大鵬薬品工業株式会社	新規安息香酸誘導体及びその製造方法
WO1992016660A1 (en)	1991-03-22	1992-10-01	Sloan-Kettering Institute For Cancer Research	Methods for detection and treatment of cancer
US5759785A (en)	1992-05-14	1998-06-02	Baylor College Of Medicine	Method of identifying hormone antagonists and agonists
US5455265A (en)	1993-02-11	1995-10-03	Allergan, Inc.	Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5824685A (en)	1995-02-01	1998-10-20	The Johns Hopkins University School Of Medicine	Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
FR2739777B1 (fr)	1995-10-11	1997-11-14	Cird Galderma	Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5675024A (en)	1995-11-22	1997-10-07	Allergan	Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en)	1995-12-29	1999-10-12	Allergan Sales, Inc.	Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR100485642B1 (ko)	1996-03-18	2005-09-30	에자이 가부시키가이샤	축합고리함유카르복실산유도체
CA2250118C (en)	1996-03-26	2009-09-29	Michael S. Kopreski	Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US5919970A (en)	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6355669B1 (en)	1997-10-22	2002-03-12	Eisai Co., Ltd.	Retinoic acid agonists as preventive and therapeutic agents for nephritis
WO2000040749A2 (en)	1999-01-06	2000-07-13	Genenews Inc.	Method for the detection of gene transcripts in blood and uses thereof
TWI281911B (en)	2000-04-04	2007-06-01	Allergan Inc	Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
WO2003025171A2 (en) *	2001-09-17	2003-03-27	Angiogene Inc.	Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
ES2395401T3 (es)	2006-03-23	2013-02-12	Tmrc Co., Ltd.	kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
MX2009009997A (es) *	2007-03-30	2009-12-08	Tmrc Co Ltd	Preparacion de la capsula de tamibarotene.
UA103319C2 (en) *	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
US20100099084A1 (en)	2008-10-17	2010-04-22	Maher Albitar	Detection of npm1 nucleic acid in acellular body fluids
WO2011097712A1 (en) *	2010-02-11	2011-08-18	The Royal Institution For The Advancement Of Learning/Mcgill University	Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties
EP2858636B1 (en) *	2012-06-07	2018-09-05	Childrens Hospital Los Angeles	Methods for treating neutropenia using retinoid agonists
EP2912178B1 (en)	2012-10-25	2020-06-17	Whitehead Institute For Biomedical Research	Super-enhancers and methods of use thereof
US20140296218A1 (en)	2012-10-25	2014-10-02	Whitehead Institute For Biomedical Research	Super-enhancers and methods of use thereof
CA2902167A1 (en)	2013-03-15	2014-09-25	Abbott Molecular Inc.	Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
EP3021866A4 (en)	2013-07-15	2017-02-22	The Board of Trustees of the Leland Stanford Junior University	Medical uses of cd38 agonists
WO2015085172A2 (en)	2013-12-06	2015-06-11	Celgene Corporation	Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US11077139B2 (en)	2013-12-30	2021-08-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
WO2016144976A1 (en)	2015-03-09	2016-09-15	Kings College London	Combination therapy with rar alpha agonists for enhancing th1 response
EP3277272B1 (en)	2015-03-31	2021-08-04	Syros Pharmaceuticals, Inc.	Methods of stratifying patients for treatment with retinoic acid receptor-agonists
WO2017091762A1 (en)	2015-11-25	2017-06-01	Io Therapeutics, Inc.	Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
KR20240157122A (ko)	2016-04-08	2024-10-31	사이로스 파마수티컬스, 인크.	Aml 및 mds 치료용 rara 효능제
TW201823471A (zh)	2016-10-06	2018-07-01	美商錫羅斯製藥公司	以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
WO2018136961A1 (en)	2017-01-23	2018-07-26	Syros Pharmaceuticals Inc.	METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY

2016
- 2016-03-31 EP EP16774191.7A patent/EP3277272B1/en active Active
- 2016-03-31 CA CA2981518A patent/CA2981518C/en active Active
- 2016-03-31 EP EP21188938.1A patent/EP3967305A1/en not_active Withdrawn
- 2016-03-31 WO PCT/US2016/025256 patent/WO2016161107A1/en not_active Ceased
- 2016-03-31 JP JP2017552074A patent/JP6952604B2/ja not_active Expired - Fee Related
- 2016-03-31 CN CN202210785569.8A patent/CN116059365A/zh active Pending
- 2016-03-31 IL IL294449A patent/IL294449B2/en unknown
- 2016-03-31 PL PL16774191T patent/PL3277272T3/pl unknown
- 2016-03-31 ES ES16774191T patent/ES2901792T3/es active Active
- 2016-03-31 BR BR112017020745-1A patent/BR112017020745A2/en not_active IP Right Cessation
- 2016-03-31 KR KR1020177030920A patent/KR20170132248A/ko not_active Ceased
- 2016-03-31 IL IL309066A patent/IL309066A/en unknown
- 2016-03-31 MX MX2017012470A patent/MX391949B/es unknown
- 2016-03-31 BR BR122023024813-9A patent/BR122023024813A2/pt not_active Application Discontinuation
- 2016-03-31 CN CN201680028129.0A patent/CN107613969B/zh not_active Expired - Fee Related
- 2016-03-31 HU HUE16774191A patent/HUE057325T2/hu unknown
- 2016-03-31 IL IL254697A patent/IL254697B/en unknown
- 2016-03-31 BR BR122023024814-7A patent/BR122023024814A2/pt unknown
- 2016-03-31 AU AU2016243702A patent/AU2016243702B2/en not_active Ceased
- 2016-06-02 US US15/172,045 patent/US9845508B2/en not_active Expired - Fee Related
2017
- 2017-09-28 MX MX2022005020A patent/MX2022005020A/es unknown
- 2017-10-31 US US15/799,519 patent/US10167518B2/en active Active
2018
- 2018-02-20 US US15/899,629 patent/US10697025B2/en active Active
2020
- 2020-05-08 US US16/870,370 patent/US11447831B2/en active Active
- 2020-08-28 JP JP2020144363A patent/JP2020203911A/ja not_active Withdrawn
2022
- 2022-01-06 AU AU2022200059A patent/AU2022200059B2/en not_active Ceased
- 2022-07-22 US US17/871,584 patent/US20230042181A1/en not_active Abandoned
- 2022-10-11 JP JP2022163053A patent/JP2022185101A/ja not_active Withdrawn
2024
- 2024-03-26 JP JP2024049322A patent/JP2024081713A/ja active Pending
- 2024-08-23 AU AU2024216311A patent/AU2024216311A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20170132248A (ko)	2017-12-01
EP3277272A4 (en)	2018-09-26
US20200392583A1 (en)	2020-12-17
CA2981518A1 (en)	2016-10-06
JP2018514517A (ja)	2018-06-07
AU2016243702A1 (en)	2017-10-26
CN107613969A (zh)	2018-01-19
IL254697B (en)	2022-08-01
BR112017020745A2 (en)	2018-07-17
AU2024216311A1 (en)	2024-09-12
US10697025B2 (en)	2020-06-30
MX2022005020A (es)	2022-05-16
US10167518B2 (en)	2019-01-01
JP6952604B2 (ja)	2021-10-20
CN116059365A (zh)	2023-05-05
MX2017012470A (es)	2018-03-23
EP3277272B1 (en)	2021-08-04
US20180087115A1 (en)	2018-03-29
BR122023024813A2 (pt)	2024-02-20
JP2020203911A (ja)	2020-12-24
CA2981518C (en)	2024-06-25
RU2017134582A (ru)	2019-04-04
US20160355888A1 (en)	2016-12-08
IL309066A (en)	2024-02-01
JP2022185101A (ja)	2022-12-13
AU2016243702B2 (en)	2021-10-07
US20180187271A1 (en)	2018-07-05
AU2022200059A1 (en)	2022-02-03
IL294449A (en)	2022-09-01
IL254697A0 (en)	2017-11-30
EP3967305A1 (en)	2022-03-16
JP2024081713A (ja)	2024-06-18
RU2017134582A3 (pl)	2019-12-13
EP3277272A1 (en)	2018-02-07
MX391949B (es)	2025-03-21
US11447831B2 (en)	2022-09-20
HUE057325T2 (hu)	2022-04-28
AU2022200059B2 (en)	2024-05-23
IL294449B1 (en)	2024-01-01
US9845508B2 (en)	2017-12-19
BR122023024814A2 (pt)	2024-02-20
ES2901792T3 (es)	2022-03-23
CN107613969B (zh)	2022-07-22
US20230042181A1 (en)	2023-02-09
WO2016161107A1 (en)	2016-10-06
IL294449B2 (en)	2024-05-01

Publication	Publication Date	Title
IL292504B1 (en)	2023-09-01	-methods of preparing t cells for t cell therapy
IL282156A (en)	2021-05-31	Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
IL254734B1 (en)	2023-05-01	Modified t cells and methods of making and using the same
IL258358A (en)	2018-06-28	Quantitative heart testing
LT3277842T (lt)	2019-10-25	Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3355734T3 (pl)	2025-03-24	Urządzenie do wytwarzania środka wdychalnego
DK3212233T3 (da)	2020-07-27	Kombinationsterapi til behandling af sygdom
SG10201913613SA (en)	2020-03-30	Methods of conditioning patients for t cell therapy
IL252087A0 (en)	2017-07-31	Methods of selecting t cell line and donor thereof for adoptive cellular therapy
DK3368060T3 (da)	2020-08-24	Glugacon-receptor-agonister
EP3068783A4 (en)	2017-08-09	Methods of treating heart failure with agonists of hypocretin receptor 2
DK3234107T3 (da)	2022-10-17	B-celler til in vivo-levering af terapeutiske midler
LT3169328T (lt)	2022-06-10	Chinolino dariniai, skirti uždegiminių ligų gydymui
ES2808978T8 (es)	2021-03-22	Heteroarilamidas como inhibidores de la agregación de proteínas
IL254697A0 (en)	2017-11-30	Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
HUE046397T2 (hu)	2020-03-30	Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása
IL257355B (en)	2021-10-31	Selection of patients for combination therapy
DK3145530T3 (da)	2021-06-14	Trail receptor agonists for treatment of fibrotic diseases
IL256127B (en)	2021-04-29	Use of benzimidazole history for nocturnal acid reflux
IL257764B (en)	2022-06-01	Methods for treatment of diseases
HUE041733T2 (hu)	2019-05-28	Intrahepatikus kolesztázisos betegségek kezelése
IL254825A0 (en)	2017-12-31	Methods of treatment with taselisib
DK3137126T3 (da)	2019-11-11	Medicinske indretninger med ikke-ensartede coatinger med henblik på forbedret ekkogenicitet
IL242220A0 (en)	2015-11-30	Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias